Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 17.14
HPTX's Cash to Debt is ranked higher than
72% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. HPTX: 17.14 )
HPTX' s 10-Year Cash to Debt Range
Min: 0.12   Max: No Debt
Current: 17.14

Equity to Asset 0.85
HPTX's Equity to Asset is ranked higher than
87% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. HPTX: 0.85 )
HPTX' s 10-Year Equity to Asset Range
Min: 0.84   Max: 0.87
Current: 0.85

0.84
0.87
F-Score: 5
Z-Score: 13.65
M-Score: 99.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -31.79
HPTX's Operating margin (%) is ranked higher than
75% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. HPTX: -31.79 )
HPTX' s 10-Year Operating margin (%) Range
Min: -31.79   Max: -31.79
Current: -31.79

Net-margin (%) 39.40
HPTX's Net-margin (%) is ranked higher than
97% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. HPTX: 39.40 )
HPTX' s 10-Year Net-margin (%) Range
Min: 39.4   Max: 39.4
Current: 39.4

ROE (%) 13.89
HPTX's ROE (%) is ranked higher than
92% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. HPTX: 13.89 )
HPTX' s 10-Year ROE (%) Range
Min: -93.82   Max: 13.89
Current: 13.89

-93.82
13.89
ROA (%) 11.67
HPTX's ROA (%) is ranked higher than
94% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. HPTX: 11.67 )
HPTX' s 10-Year ROA (%) Range
Min: -361.29   Max: 11.67
Current: 11.67

-361.29
11.67
ROC (Joel Greenblatt) (%) -1433.44
HPTX's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. HPTX: -1433.44 )
HPTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -137678.95   Max: -1433.44
Current: -1433.44

-137678.95
-1433.44
» HPTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

HPTX Guru Trades in

Q1 2013

HPTX Guru Trades in Q1 2013

RS Investment Management 74,900 sh (New)
Steven Cohen 125,000 sh (New)
Louis Moore Bacon 15,000 sh (New)
» More
Q2 2013

HPTX Guru Trades in Q2 2013

Louis Moore Bacon Sold Out
Steven Cohen Sold Out
RS Investment Management 73,078 sh (-2.43%)
» More
Q3 2013

HPTX Guru Trades in Q3 2013

RS Investment Management Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with HPTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 17.90
HPTX's P/E(ttm) is ranked higher than
97% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HPTX: 17.90 )
HPTX' s 10-Year P/E(ttm) Range
Min: 18   Max: 177.55
Current: 17.9

18
177.55
P/B 3.80
HPTX's P/B is ranked higher than
80% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. HPTX: 3.80 )
HPTX' s 10-Year P/B Range
Min: 3.24   Max: 5.76
Current: 3.8

3.24
5.76
P/S 8.10
HPTX's P/S is ranked higher than
81% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. HPTX: 8.10 )
HPTX' s 10-Year P/S Range
Min: 8.12   Max: 516.4
Current: 8.1

8.12
516.4
PFCF 32.00
HPTX's PFCF is ranked higher than
94% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HPTX: 32.00 )
HPTX' s 10-Year PFCF Range
Min: 32   Max: 40.65
Current: 32

32
40.65
EV-to-EBIT -132.24
HPTX's EV-to-EBIT is ranked higher than
52% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HPTX: -132.24 )
HPTX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -132.24

Current Ratio 6.34
HPTX's Current Ratio is ranked higher than
82% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. HPTX: 6.34 )
HPTX' s 10-Year Current Ratio Range
Min: 0.11   Max: 11.32
Current: 6.34

0.11
11.32
Quick Ratio 6.20
HPTX's Quick Ratio is ranked higher than
82% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. HPTX: 6.20 )
HPTX' s 10-Year Quick Ratio Range
Min: 0.11   Max: 11.27
Current: 6.2

0.11
11.27

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.70
HPTX's Price/Net Cash is ranked higher than
92% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. HPTX: 4.70 )
HPTX' s 10-Year Price/Net Cash Range
Min: 4.32   Max: 5.95
Current: 4.7

4.32
5.95
Price/Net Current Asset Value 4.60
HPTX's Price/Net Current Asset Value is ranked higher than
91% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. HPTX: 4.60 )
HPTX' s 10-Year Price/Net Current Asset Value Range
Min: 4.32   Max: 5.89
Current: 4.6

4.32
5.89
Price/Tangible Book 4.20
HPTX's Price/Tangible Book is ranked higher than
83% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. HPTX: 4.20 )
HPTX' s 10-Year Price/Tangible Book Range
Min: 3.83   Max: 5.76
Current: 4.2

3.83
5.76
Price/Median PS Value 0.40
HPTX's Price/Median PS Value is ranked higher than
96% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. HPTX: 0.40 )
HPTX' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 24.36
Current: 0.4

0.43
24.36
Price/Graham Number 1.80
HPTX's Price/Graham Number is ranked higher than
96% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HPTX: 1.80 )
HPTX' s 10-Year Price/Graham Number Range
Min: 2.02   Max: 5.53
Current: 1.8

2.02
5.53

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0HY.Germany
Hyperion Therapeutics Inc was incorporated under the laws of the State of Delaware in November 2006. It is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. The Company's product candidate, Ravicti (glycerol phenylbutyrate), is designed to lower ammonia in the blood. Ammonia is produced in the intestine after a person eats protein and is normally detoxified in the liver by conversion to urea. Elevated levels of ammonia are potentially toxic and can lead to severe medical complications which may include death. It is developing Ravicti to treat two different diseases in which blood ammonia is elevated: the prevalent urea cycle disorders, or UCD, and hepatic encephalopathy, or HE. UCD are inherited rare genetic diseases caused by a deficiency of one or more enzymes or protein transporters that constitute the urea cycle, which in a healthy individual removes ammonia through the conversion of ammonia to urea. HE may develop in some patients with liver scarring, known as cirrhosis, or acute liver failure and is a chronic disease which fluctuates in severity and may lead to serious neurological damage. The Company's strategy is to commercialize a product portfolio, including Ravicti, for the treatment of UCD and to develop Ravicti for the treatment of HE and other indications. Hyperion acquired the worldwide rights to Ravicti from Ucyclyd Pharma, Inc, a wholly owned subsidiary of Medicis Pharmaceutical Corporation in March 2012. Hyperion also has an option to acquire, in the first half of 2013 for a pre-negotiated price; Hyperion also has an option to acquire, in the first half of 2013 for a pre-negotiated price, Ucyclyd's worldwide rights to BUPHENYL and, subject to certain conditions, AMMONUL.
» More Articles for HPTX

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
HYPERION THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Jul 21 2014
HYPERION THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 08 2014
Hyperion's Ravicti Submission Accepted in EU Jun 26 2014
Hyperion says EMA to review of marketing authorization application for RAVICTI Jun 25 2014
Hyperion Therapeutics Announces EMA Acceptance for Review of Marketing Authorization Application for... Jun 25 2014
Hyperion Therapeutics to Present at the JMP Healthcare Conference Jun 18 2014
HYPERION THERAPEUTICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Jun 13 2014
Hyperion Therapeutics to Present at 2014 Wells Fargo Healthcare Conference Jun 12 2014
Hyperion Therapeutics Completes Acquisition of Andromeda Biotech, Ltd. Jun 12 2014
Hyperion (HPTX) in Focus: Stock Tumbles 9.5% Jun 09 2014
HYPERION THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure Jun 06 2014
Hyperion Therapeutics Announces Health Canada Accepts RAVICTI(R) New Drug Submission With Priority... Jun 03 2014
Hyperion Therapeutics to Present at Jefferies 2014 Global Healthcare Conference May 28 2014
HYPERION THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 28 2014
HYPERION THERAPEUTICS INC Financials May 16 2014
HYPERION THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report May 07 2014
Hyperion Therapeutics to Present at Bank of America Merrill Lynch 2014 Health Care Conference May 07 2014
Hyperion Therapeutics' (HPTX) CEO Don Santel on Q1 2014 Results - Earnings Call Transcript May 07 2014
HYPERION THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide